GlucoTrack
GlucoTrack is a pre-revenue, clinical-stage medical device company developing a fully implantable continuous blood glucose monitoring system that measures glucose directly from blood with up to 3-year sensor longevity, targeting people with diabetes on intensive insulin therapy.
- Company typePublic
- Founded1999
- HeadquartersRutherford, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What GlucoTrack does
GlucoTrack, Inc. (NASDAQ: GCTK) is a pre-revenue, clinical-stage medical device company developing a fully implantable Continuous Blood Glucose Monitoring (CBGM) system that measures glucose directly from blood rather than interstitial fluid. The system comprises an intravascular sensor lead implanted into the subclavian vein, subcutaneous electronics, and a mobile application, designed for up to 3-year sensor longevity with minimal calibration and no on-body wearable component. The device is investigational, limited by U.S. federal law to investigational use only, and is targeting FDA IDE clearance to enable a U.S. clinical study and a commercial launch targeted for the second half of 2026. The lead clinical data — a first-in-human study at Instituto do Coração in São Paulo (n=10, MARD 7.7%, 99% data capture, no SAEs) and a 240-day ovine study (34 devices, MARD 6.8%, no device-related adverse events) — supports the differentiated technical claim versus 7–15-day subcutaneous CGM competitors.
The company's revenue model is hardware sales of the implantable CBGM through hospital procurement channels, with implantation performed by interventional cardiologists using established percutaneous techniques. Go-to-market preparation includes dual-source U.S. contract manufacturing, an engaged U.S. CRO, an identified U.S. reimbursement pathway, ISO 13485:2016 certification (February 2025), three USPTO patents (October–November 2025), and partnerships spanning OneTwo Analytics (AI/ML analytics), TTP (independent sensor longevity characterization), the FORGETDIABETES consortium (EU bionic pancreas integration), and feasibility study sites in Brazil and Australia. The customer segments targeted are people with Type 1 or Type 2 diabetes on intensive insulin therapy, with a secondary evaluation underway in Painful Diabetic Neuropathy (PDN) via spinal cord stimulation integration.
GlucoTrack is headquartered in Rutherford, New Jersey (Delaware corporation), with historical R&D operations in Or Yehuda, Israel inherited from predecessor Integrity Applications, Inc. (renamed March 2022). The company is publicly listed but trades at an extremely compressed market capitalization (~$1.1M–$3.5M), has executed two reverse stock splits in 2025, and received Nasdaq delisting notices in May 2026, while continuing to fund clinical and regulatory milestones through a series of small public offerings and private placements totaling approximately $25M since April 2024.
GlucoTrack firmographics
Firmographics- Name
- GlucoTrack
- Legal name
- Glucotrack, Inc.
- Website
- https://glucotrack.com/
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GlucoTrack is a pre-revenue, clinical-stage medical device company developing a fully implantable continuous blood glucose monitoring system that measures glucose directly from blood with up to 3-year sensor longevity, targeting people with diabetes on intensive insulin therapy.
- Ownership category
- akta.pro rank
GlucoTrack industry classification
Industry- Product category
- Continuous Glucose Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)
Keywords
Where GlucoTrack is headquartered
LocationHeadquarters
- HQ city
- Rutherford
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
GlucoTrack business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Implantable CBGM Device Sales: GlucoTrack is pre-revenue and has not yet commercialized its CBGM technology. The company is a medical device developer targeting the continuous glucose monitoring market. The anticipated commercial model would involve the sale of implantable medical devices, likely through hospital procurement channels with reimbursement coding. The company has identified a U.S. reimbursement pathway to support commercial execution.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
GlucoTrack product offering
Product offeringCore offering
GlucoTrack is developing a fully implantable Continuous Blood Glucose Monitor (CBGM) system that measures glucose directly from blood in real time via an intravascular sensor lead implanted into the subclavian vein, connected to subcutaneous electronics and a mobile application. The device is designed for up to 3-year sensor longevity, eliminating the external wearable component and frequent sensor replacements required by conventional CGMs. The product is investigational (not yet FDA approved), with IDE application submitted to the FDA in May 2026 and U.S. commercial launch targeted for H2 2026.
Product overview
GlucoTrack is developing a single unified product: the Continuous Blood Glucose Monitor (CBGM) system, which is a fully implantable device designed for long-term continuous blood glucose monitoring. The system comprises an intravascular sensor lead implanted into the subclavian vein, subcutaneous electronics for signal processing, and a mobile application for data display. Unlike traditional CGMs that measure interstitial fluid, the CBGM measures glucose directly from blood, eliminating lag time. The device is designed for multi-year sensor longevity (up to 3 years), with no external wearable component, representing a differentiated approach to diabetes management. The product is currently investigational and has not received FDA approval.
Differentiator
Problem solved
Functional benefit
Products and services
- Continuous Blood Glucose Monitor (CBGM) A fully implantable continuous blood glucose monitoring system designed to measure glucose directly from blood in real time for up to 3 years. The system consists of an intravascular sensor lead implanted into the subclavian vein via established percutaneous techniques performed by interventional cardiologists, connected to subcutaneous electronics, and communicating with a mobile application for data display. Eliminates on-body wearable components and disposable sensors required by conventional CGMs, and measures directly from blood rather than interstitial fluid to eliminate lag time. The product is investigational and not yet FDA approved, with IDE application submitted May 2026.
Quantifiable outcome
- MARD of 7.7% across 122 matched pairs with 99% data capture rate and no procedure or device-related serious adverse events in first-in-human clinical study (n=10, Brazil, Dec 2024-Jan 2025)
- +3 more outcomes
Companies that use GlucoTrack
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
GlucoTrack technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature8 records
GlucoTrack partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- TTP (The Technology Partnership)coreGlucoTrack partnered with TTP, a UK-based scientific and engineering organization, for an independent third-party study and publication on the year-long in-vitro characterization of glucose oxidase enzyme decay in electrochemical glucose sensors. The study, published in IEEE Sensors Journal (April 2026), provided externally reviewed scientific evidence supporting the feasibility of long-life implantable glucose sensors. TTP is recognized in the medtech industry for supporting life sciences and medical device innovation.
- Unnamed U.S. Clinical Research Organization (CRO)coreGlucoTrack has engaged a Clinical Research Organization experienced with diabetes Medtech to manage and conduct its planned U.S. clinical study. CRO engagement is part of the company's clinical trial readiness activities for its IDE submission with the FDA.
- Unnamed Dual-Source U.S. Contract Manufacturing PartnerscoreGlucoTrack has established a dual-source U.S. manufacturing strategy with two qualified contract manufacturing partners for its CBGM system. This dual-source approach is intended to ensure supply chain resilience and manufacturing capacity for commercial launch.
- St. Vincent's Hospital Melbourne (Diabetes Technology Research Group)coreGlucoTrack initiated a feasibility clinical trial at the Diabetes Technology Research Group of St. Vincent's Hospital in Melbourne, Australia. Ethical approval was received from St. Vincent's Ethics Committee. The study provided protocol and product learnings for the planned U.S. clinical study.
- OneTwo Analytics ABcoreGlucoTrack entered into a collaboration agreement with OneTwo Analytics AB, a Sweden-based healthtech company specializing in AI-driven analytics for diabetes data, CGM analysis, and clinical study data evaluation. The partnership leverages next-generation AI and machine learning analytics to evaluate clinical study data from GlucoTrack's CBGM technology, providing enhanced insights into performance and clinical value. OneTwo Analytics has also collaborated on the first-in-human clinical study analysis presented at ADA 2025.
- FORGETDIABETES ConsortiumcoreGlucoTrack announced its participation in the FORGETDIABETES consortium, a prominent European research initiative to develop a bionic pancreas. Under this partnership, GlucoTrack's CBGM technology will be integrated with an automated insulin delivery system for a major EU diabetes study.
- Instituto do Coração (São Paulo, Brazil)coreFirst-in-human clinical study conducted at the Interventional Cardiology department of Instituto do Coração in São Paulo, Brazil. Insertion and removal procedures were performed by interventional cardiologists using established percutaneous techniques. Study enrolled 10 participants with Type 1 or Type 2 diabetes on intensive insulin therapy.
- Dawson James Securities, Inc.minorDawson James Securities acted as the sole placement agent for GlucoTrack's $10.0 million public offering in November 2024 and the $3.0 million public offering in February 2025. Capital markets advisory and securities placement services.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
GlucoTrack competitors and assessment
Company assessmentBroad incumbents
- DexCom: Market-leading CGM manufacturer (G6/G7) with dominant share in intermittent subcutaneous CGMs. Highly comparable as the benchmark GlucoTrack must displace on accuracy, longevity and patient burden; multiple GlucoTrack executives are former DexCom R&D leaders.
- Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre franchise is the global volume leader in factory-calibrated CGMs. Directly comparable as the incumbent disposable-wear CGM GlucoTrack's 3-year implantable alternative is positioned against.
- Medtronic Diabetes (Guardian / Simplera): Medtronic's Guardian CGM integrates with its MiniMed insulin pumps for closed-loop delivery. Comparable as a CGM incumbent pursuing automated insulin delivery — the same end market GlucoTrack is targeting via the FORGETDIABETES consortium.
- Insulet Corporation: Maker of the Omnipod tubeless insulin pump, a key participant in automated insulin delivery. Comparable because GlucoTrack's CBGM is being positioned as a sensing front-end for AID systems that include Insulet-class pumps.
- Tandem Diabetes Care: Developer of the t:slim X2 insulin pump with Control-IQ AID algorithm. Comparable as a diabetes device incumbent that consumes CGM data; a logical integration partner if GlucoTrack's CBGM reaches commercialization.
Direct peers
- Senseonics Holdings (Eversense): Developer of the Eversense implantable CGM (180–365 day sensor, external transmitter). The closest direct peer: also a long-duration implantable CGM, also pursuing Class III PMA, and a prior employer of multiple GlucoTrack regulatory and clinical executives.
- GlySens (acquired): Former developer of a fully implantable long-term glucose sensor. Highly comparable as a prior-generation implantable CGM platform; multiple GlucoTrack clinical and regulatory executives (Martha, Williams) came directly from GlySens and bring that institutional knowledge.
Emerging players
- Beta Bionics: Developer of the iLet bionic pancreas system. Comparable as a fellow member/adjacent participant of the FORGETDIABETES consortium pursuing fully automated insulin delivery that will require high-accuracy continuous sensing.
- Intuity Medical: Developer of the POGO Automatic blood glucose monitor — an integrated, multi-test BGM system. Comparable as another small-cap diabetes device company commercializing a differentiated glucose measurement platform; GlucoTrack's VP Marketing previously led commercial strategy there.
Others
- OneTwo Analytics: Sweden-based AI/ML analytics provider for CGM and diabetes clinical study data. Comparable as GlucoTrack's core AI/data analytics partner that co-developed the first-in-human study analysis presented at ADA 2025.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
GlucoTrack social profiles
Digital presenceGlucoTrack compliance and trust
Trust signalCompliance1 record
GlucoTrack financial estimates
Financial estimateRevenue estimate
Valuation estimate
GlucoTrack leadership team
Management profileNumber of profiles
Profiles7 records
GlucoTrack funding detail
Funding detailFunding overview
Funding rounds18 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GlucoTrack M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GlucoTrack
What does GlucoTrack do?
GlucoTrack is developing a fully implantable Continuous Blood Glucose Monitor (CBGM) system that measures glucose directly from blood in real time via an intravascular sensor lead implanted into the subclavian vein, connected to subcutaneous electronics and a mobile application. The device is designed for up to 3-year sensor longevity, eliminating the external wearable component and frequent sensor replacements required by conventional CGMs. The product is investigational (not yet FDA approved), with IDE application submitted to the FDA in May 2026 and U.S. commercial launch targeted for H2 2026.
Is GlucoTrack a public or private company?
GlucoTrack is a public company. It is classified as public and is currently operating.
When was GlucoTrack founded?
GlucoTrack was founded in 1999. It employs 11 to 50 people.
Where is GlucoTrack based?
GlucoTrack is headquartered in Rutherford, United States, in the North America region.
How does GlucoTrack make money?
One revenue line is on record: implantable CBGM Device Sales.
Who are GlucoTrack's main competitors?
Broad incumbents on record are DexCom, Abbott Diabetes Care (FreeStyle Libre), Medtronic Diabetes (Guardian / Simplera), Insulet Corporation and Tandem Diabetes Care. Direct peers are Senseonics Holdings (Eversense) and GlySens (acquired). Emerging players are Beta Bionics and Intuity Medical. OneTwo Analytics is listed as an others.
Does GlucoTrack have an API?
No public API is recorded for GlucoTrack.
What industry is GlucoTrack in?
GlucoTrack's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems. Its NAICS code is 334510 and its SIC code is 3845.